#USA #Palo Alto #Paradise System #Recor Medical #World Hypertension Day

Recor Medical Celebrates World Hypertension Day 2026

On May 17, 2026, the world will acknowledge World Hypertension Day, a significant date for raising awareness about hypertension, a condition affecting over a billion people globally. Recor Medical, Inc., a subsidiary of Otsuka Medical Devices Co., Ltd., is once again at the forefront, emphasizing the essential role of innovation and global engagement in combating this serious health risk.

Hypertension, often termed the “silent killer,” has seen an alarming rise in prevalence, with the World Health Organization reporting an increase from 650 million adults in 1990 to 1.3 billion by 2019. This condition poses serious threats such as heart attacks, strokes, and kidney diseases, highlighting the urgent need for ongoing education, detection, and treatment advancements.

The 2026 theme, “Together Against Hypertension,” stresses the importance of early detection and sustainable treatment pathways for longer, healthier lives. According to the WHO, many patients struggle to keep their blood pressure under control, even when adhering to healthy lifestyle practices and multiple medications. This statistic underscores the necessity for new treatment approaches.

Among these innovations is the renal denervation with ultrasound (uRDN), a minimally invasive medical technique aimed at reducing the overactive sympathetic nerve activity contributing to hypertension. Recor Medical’s specially designed Paradise™ uRDN system utilizes ultrasound energy to calm the overactive nerves around the renal arteries, offering a potential new treatment option for suitable patients.

Helen Reeve-Stoffer, CEO of Recor Medical, stated, “World Hypertension Day serves as a poignant reminder that we need to do more to bridge the gap between diagnosis and control. Our mission at Recor is to advance innovative solutions that extend beyond traditional therapies, empowering physicians to better treat patients whose blood pressure remains uncontrolled despite lifestyle changes and medication.”

Dr. Shon Chakrabarti, Chief Medical Officer at Recor Medical, further emphasized the importance of addressing hypertension as a significant modifiable risk factor within medicine. He remarked, “We are entering a new era of hypertension treatment, where device-based therapies, such as the Paradise procedure, can aid in lowering blood pressure alongside traditional medications and lifestyle adjustments.” This new focus on technology aims to broaden the scope of treatment and ultimately help more patients maintain sustainable and significant reductions in blood pressure.

Understanding the Paradise uRDN System

The Paradise uRDN System is a groundbreaking ultrasound-based approach designed to effectively lower blood pressure. It targets the sympathetic nerves around the arteries supplying the kidneys, reducing their overactivity which can lead to hypertension. The device administers two to three waves of 360-degree ultrasound energy, lasting seven seconds each, to the surrounding nerves, utilizing a specialized HydroCooling™ system to protect the arterial walls during the procedure.

Currently, the Paradise uRDN system is available for patients in the United States, having received FDA approval in November 2023. It serves as an adjunct therapy for those whose hypertension remains inadequate despite lifestyle modifications and pharmacological treatments. Potential side effects may include pain at the access site and transient vasospasms, emphasizing that individual treatment results can vary.

About Recor Medical, Inc.

Recor Medical, headquartered in Palo Alto, California, is dedicated to revolutionizing the treatment landscape for resistant hypertension through its innovative Paradise™ system. The company boasts FDA approval, CE marking, and regulatory endorsements in markets recognizing these designs. They are committed to advancing treatment options through clinical data collection and ongoing research, ensuring patients have access to effective hypertension management methods.

In conclusion, as World Hypertension Day 2026 approaches, Recor Medical is amplifying the conversation around hypertension and advancing critical innovations aimed at improving patient health outcomes globally. For more information about the Paradise uRDN system and the ongoing fight against hypertension, visit Recor Medical.